IL2 and neoplasm: Muromonab-CD3 was reported to significantly decrease CD3+ tumor cells in a patient with refractory T cell acute lymphoblastic leukemia (266), but was ineffective in enhancing immune activation in patients with solid tumors when administered in combination with high- or low-dose IL-2 (267, 268).